ADEPTS (accelerated diagnosis of neuroendocrine and pancreatic tumours) and EDRA (early diagnosis research alliance)

Stephen Pereira, Julia Hippisley-Cox, John Timms, Justin Hsuan, Giuseppe Kito Fusai, Norman Williams, Eithne Costello, Bill Greenhalf, Chiara Braconi, Melody Zhifang Ni, Robert van der Meer, Chris Macdonald

Research output: Contribution to journalMeeting abstractpeer-review


Pancreatic neuroendocrine tumours (PNETs) and pancreatic adenocarcinoma (PDAC) are often diagnosed at an incurable stage when already spread outside the pancreas. If we could detect these tumours at an earlier stage, we could treat them with surgery so that more people would survive these diseases. To deliver early diagnosis for people with these cancers the Early Diagnosis Research Alliance (EDRA) commenced in 2019 and encompasses four complementary work packages: 1) Improve early symptom identification in patients with PNETs and PDAC, using CALIBER (UCL Institute of Health Informatics) and QResearch (U Oxford) resources; 2) Support blood biomarker discovery and validation programmes to develop ultrasensitive combined biomarker panels for early PNETs and PDAC; 3) Develop a large multicentre prospective blood sample resource in patients with non-specific but concerning symptoms (assessed by CDSTs: cancer decision support tools) attending endoscopy, clinics and rapid diagnostic centres; 4) Perform a stakeholder analysis, assess barriers to adoption and health economic studies to support early detection of pancreatic cancers. The EDRA includes the Accelerated Diagnosis of neuroEndocrine and Pancreaticobiliary TumourS (ADEPTS) Study (IRAS Number: 234637, NIHR Portfolio no. 7343). This study is a component of work package 3 and acts as the ethical framework for the national EDRA.
Original languageEnglish
Pages (from-to)e14
Number of pages1
Issue number8
Early online date23 Nov 2020
Publication statusPublished - 1 Dec 2020
EventThe London Pancreas Workshop 2020: A forum for state-of-the-art clinical and basic research in pancreatic cancer - Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Duration: 11 Sep 202011 Sep 2020


  • pancreatic ductal adenocarcinoma
  • pancreatic neuroendocrine tumours
  • Early Diagnosis Research Alliance
  • biomarkers
  • early detection of cancer


Dive into the research topics of 'ADEPTS (accelerated diagnosis of neuroendocrine and pancreatic tumours) and EDRA (early diagnosis research alliance)'. Together they form a unique fingerprint.

Cite this